|Mr. Rick E. Winningham||Chairman & CEO||1.73M||N/A||1960|
|Mr. Bradford J. Shafer||Exec. VP, Gen. Counsel & Sec.||868.58k||N/A||1960|
|Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A.||Sr. VP of Corp. Devel. & Strategy||N/A||N/A||1973|
|Dr. Brett K. Haumann||Sr. VP of Clinical Devel. & Chief Medical Officer||1.26M||N/A||1970|
|Ms. Jessica Stitt||VP of Fin. and Investor Relations||N/A||N/A||N/A|
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant. YUPELRI, a long-acting muscarinic antagonist, for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD); and Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders. The company's product candidates also comprise Selective 5-HT4 Agonist for treating gastrointestinal motility disorders; Gut-selective Pan-Janus Kinase Inhibitor Program for treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis; TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TD-0714 and Neprilysin Inhibitor Program, which have completed Phase I clinical studies for heart failure and chronic kidney disease, including diabetic nephropathy. In addition, it focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium bromide, and vilanterol for the treatment of COPD and asthma; the inhaled bifunctional muscarinic antagonist-beta2 agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
Theravance Biopharma, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 9; Compensation: 7.